314298-15-2

Usage

Uses

Used in Pharmaceutical Industry:
1-Bromo-4-fluoro-2-methoxy-5-methylbenzene is used as a key intermediate in the synthesis of (arylcarbamoylphenoxy)acetic acid inhibitors of aldose reductase. These inhibitors are being studied for their potential in treating chronic diabetic complications, such as diabetic neuropathy, retinopathy, and nephropathy. 1-Bromo-4-fluoro-2-methoxy-5-methylbenzene's unique structure allows for the development of new and effective drugs that can target and inhibit aldose reductase, an enzyme implicated in the development of these complications.
Additionally, 1-Bromo-4-fluoro-2-methoxy-5-methylbenzene can be used as a building block in the synthesis of other bioactive molecules, such as antibiotics, anti-inflammatory agents, and analgesics. Its versatile functional groups enable various chemical reactions, allowing for the creation of a wide range of pharmaceutical agents with different therapeutic properties.
Used in Agrochemical Industry:
1-Bromo-4-fluoro-2-methoxy-5-methylbenzene can also be utilized in the development of agrochemicals, such as herbicides, insecticides, and fungicides. Its unique structure and functional groups can be exploited to design novel compounds with improved efficacy, selectivity, and environmental safety. By incorporating 1-Bromo-4-fluoro-2-methoxy-5-methylbenzene into the synthesis of agrochemicals, researchers can develop new products that are more effective in controlling pests and diseases while minimizing the impact on non-target organisms and the environment.

Upstream product

• 314298-13-0 1-fluoro-5-methoxy-2-methyl-4-nitro-benzene 
• 1268511-85-8 2-bromo-5-fluoro-4-methylphenol 
• 74-88-4 methyl iodide 
• 314298-14-1 4-fluoro-2-methoxy-5-methyl-phenylamine 
• 106579-00-4 5-methoxy-2-methyl-4-nitroaniline 

Downstream Products

• 314298-16-3 4-fluoro-2-methoxy-5-methyl-benzonitrile 
• 314298-17-4 4-fluoro-2-methoxy-5-methyl-benzoic acid 
• 314298-19-6 N-(4-bromo-2-fluorobenzyl)-4-fluoro-2-hydroxy-5-methyl-benzamide 
• 314298-18-5 N-(4-bromo-2-fluorobenzyl)-4-fluoro-2-methoxy-5-methyl-benzamide 
• 314298-20-9 [2-(4-bromo-2-fluorobenzylcarbamoyl)-5-fluoro-4-methyl-phenoxy]-acetic acid ethyl ester 
• 314298-21-0 [2-(4-bromo-2-fluorobenzylthiocarbamoyl)-5-fluoro-4-methyl-phenoxy]-acetic acid ethyl ester 

Relevant academic research and scientific papers

COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN

The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Design and synthesis of highly potent and selective (2-arylcarbamoyl- phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications

Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid aldose reductase inhibitors. The compound class features a core template that utilizes an intramolecular hydrogen bond to position the key structural elements of the pharmacophore in a conformation, which promotes a high binding affinity. The lead candidate, example 40, 5-fluoro-2-(4-bromo-2-fluoro-benzylthiocarbamoyl)-phenoxyacetic acid, inhibits aldose reductase with an IC50 of 30 nM, while being 1100 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. In addition, example 40 lowers nerve sorbitol levels with an ED50 of 31 mg/kg/d po in the 4-day STZ-induced diabetic rat model.

Substituted phenoxyacetic acids

Disclosed are substituted phenoxyacetic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds, alone or in combination with other therapeutic agents, and methods of treatment employing the compounds and pharmaceutical compositions, as well as methods for their synthesis.